Personalized Medicine Key to Treating Squamous Cell Lung Cancers
New data published in Nature from the Cancer Genome Atlas shows that many squamous cell lung cancers can benefit from personalized medicine and targeted therapies.
Led by a team of researchers including UALC Medical Committee member and past UALC grantee Dr. Matthew Meyerson, the study investigated the genetics of squamous cell lung cancer. Squamous cell carcinoma accounts for about 25% of lung cancers - corresponding to roughly 56,000 new diagnoses each year.
They found that like adenocarcinoma, the most common form of lung cancer, squamous cell carcinoma has diverse genetic causes - many of which can potentially be blocked by drugs. The successes seen in treating adenocarcinoma, the most common type of lung cancer, may be replicated to treat squamous cell lung cancer.
You can read a great article in the New York Times covering this breakthrough from the Cancer Genome Atlas team here, with quotes from UALC Medical Committee members Dr. Meyerson and Dr. William Pao: http://www.nytimes.com/2012/09/10/health/research/for-a-lung-cancer-drug-treatment-may-be-within-reach.html?ref=ginakolata